Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

[Application of neoadjuvant hormonal therapy in (125)I permanent seed implantation for prostate cancer].

Cui X, Li Q, Xu JJ, Li J, Ou TW.

Zhonghua Yi Xue Za Zhi. 2012 Oct 16;92(38):2710-2. Chinese.

PMID:
23290112
2.

[Impact of neoadjuvant hormonal therapy on the permanent ¹²⁵I-seed brachytherapy for localized high-risk prostate cancer].

Zhuang HY, Xu XM, Peng T, Lin CP.

Zhonghua Yi Xue Za Zhi. 2010 Dec 28;90(48):3418-20. Chinese.

PMID:
21223817
4.

Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: importance of patient selection and implant quality.

Kollmeier MA, Stock RG, Stone N.

Int J Radiat Oncol Biol Phys. 2003 Nov 1;57(3):645-53.

PMID:
14529768
5.

Five-year biochemical outcome following permanent interstitial brachytherapy for clinical T1-T3 prostate cancer.

Merrick GS, Butler WM, Galbreath RW, Lief JH.

Int J Radiat Oncol Biol Phys. 2001 Sep 1;51(1):41-8.

PMID:
11516849
6.

Relationship between percent positive biopsies and biochemical outcome after permanent interstitial brachytherapy for clinically organ-confined carcinoma of the prostate gland.

Merrick GS, Butler WM, Galbreath RW, Lief JH, Adamovich E.

Int J Radiat Oncol Biol Phys. 2002 Mar 1;52(3):664-73.

PMID:
11849788
7.

Four-year biochemical outcome after radioimmunoguided transperineal brachytherapy for patients with prostate adenocarcinoma.

Ellis RJ, Vertocnik A, Kim E, Zhou H, Young B, Sodee B, Fu P, Beddar S, Colussi V, Spirnak JP, Dinchman KH, Resnick M, Kinsella TJ.

Int J Radiat Oncol Biol Phys. 2003 Oct 1;57(2):362-70.

PMID:
12957246
8.

Five-year biochemical outcome and toxicity with transperineal CT-planned permanent I-125 prostate implantation for patients with localized prostate cancer.

Zelefsky MJ, Hollister T, Raben A, Matthews S, Wallner KE.

Int J Radiat Oncol Biol Phys. 2000 Jul 15;47(5):1261-6.

PMID:
10889379
9.
11.

Urinary symptom flare following I-125 prostate brachytherapy.

Cesaretti JA, Stone NN, Stock RG.

Int J Radiat Oncol Biol Phys. 2003 Jul 15;56(4):1085-92.

PMID:
12829146
12.

PSA bounce predicts early success in patients with permanent iodine-125 prostate implant.

Patel C, Elshaikh MA, Angermeier K, Ulchaker J, Klein EA, Chehade N, Wilkinson DA, Reddy CA, Ciezki JP.

Urology. 2004 Jan;63(1):110-3.

PMID:
14751360
13.

Analysis of prostate-specific antigen bounce after I(125) permanent seed implant for localised prostate cancer.

Mitchell DM, Swindell R, Elliott T, Wylie JP, Taylor CM, Logue JP.

Radiother Oncol. 2008 Jul;88(1):102-7. doi: 10.1016/j.radonc.2008.04.004. Epub 2008 Apr 29.

PMID:
18453022
14.

125I brachytherapy for localized prostate cancer: a single institution experience.

Guarneri A, Botticella A, Filippi AR, Munoz F, Beltramo G, Casetta G, Giglioli FR, Tizzani A, Ragona R, Ricardi U.

Tumori. 2013 Jan-Feb;99(1):83-7. doi: 10.1700/1248.13793.

PMID:
23549005
15.

Prostate-specific antigen relapse-free survival and side-effects in 734 patients with up to 10 years of follow-up with localized prostate cancer treated by permanent iodine implants.

Prada PJ, Juan G, González-Suárez H, Fernández J, Jimenez I, Amón J, Cepeda M.

BJU Int. 2010 Jul;106(1):32-6. doi: 10.1111/j.1464-410X.2009.09096.x. Epub 2010 Jan 8.

16.

Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects.

Gleave ME, Goldenberg SL, Chin JL, Warner J, Saad F, Klotz LH, Jewett M, Kassabian V, Chetner M, Dupont C, Van Rensselaer S; Canadian Uro-Oncology Group..

J Urol. 2001 Aug;166(2):500-6; discussion 506-7.

PMID:
11458055
17.

Prostate-specific antigen kinetics after brachytherapy or external beam radiotherapy and neoadjuvant hormonal therapy.

Pinkawa M, Fischedick K, Piroth MD, Gagel B, Borchers H, Jakse G, Eble MJ.

Urology. 2007 Jan;69(1):129-33.

PMID:
17270634
18.

Improved conformality and decreased toxicity with intraoperative computer-optimized transperineal ultrasound-guided prostate brachytherapy.

Zelefsky MJ, Yamada Y, Marion C, Sim S, Cohen G, Ben-Porat L, Silvern D, Zaider M.

Int J Radiat Oncol Biol Phys. 2003 Mar 15;55(4):956-63.

PMID:
12605973
19.

High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds.

Grills IS, Martinez AA, Hollander M, Huang R, Goldman K, Chen PY, Gustafson GS.

J Urol. 2004 Mar;171(3):1098-104.

PMID:
14767279
20.

Association of neoadjuvant hormonal therapy with adverse health-related quality of life after permanent iodine-125 brachytherapy for localized prostate cancer.

Pinkawa M, Fischedick K, Gagel B, Piroth MD, Borchers H, Jakse G, Eble MJ.

Urology. 2006 Jul;68(1):104-9. Epub 2006 Jun 27.

PMID:
16806434

Supplemental Content

Support Center